• Ruxolitinib

    ʻO Ruxolitinib

    Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika)
    ʻO Ruxolitinib Myelofibrosis Novartis Iulai 6, 2024
  • Crisaborole

    Crisaborole

    Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika)
    Crisaborole ʻO ka Dermatitis Atopic a me ka Eczema Pfizer Iune 11, 2026 
  • Relugolix

    Relugolix

    Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika)
    Relugolix Ka maʻi maʻi prostate Takeda a me ASKA Ian. 24, 2024
  • Vericiguat

    Vericiguat

    Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika)
    Vericiguat Puuwai poho Bayer a me MSD Mei.24, 2031
  • Abrocitinib

    Abrocitinib

    Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika)
    Abrocitinib ʻO ka Dermatitis Atopic Pfizer Feb.11, 2034
  • Rimegepant

    Rimegepant

    Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika)
    Rimegepant ʻO ka migraine headache Biohaven Feb. 22, 2031

     

  • Elagolix 834153-87-6

    Elagolix 834153-87-6

    Ka inoa o ka API Hōʻike Hōʻike US DMF EU DMF CEP
    ElagolixCAS:834153-87-6 Endometriosis I-Hale      
  • Relugolix 737789-87-6

    Relugolix 737789-87-6

    Ka inoa o ka API Hōʻike Hōʻike US DMF EU DMF CEP
    Ribociclib CAS: 737789-87-6 Atineoplastic I-Hale      
  • Venetoclax 1257044-40-8

    Venetoclax 1257044-40-8

    Ka inoa o ka API Hōʻike Mea hana hou Lā Hoʻopau Patent (ʻAmelika)
    Venetoclax 1257044-40-8 CLL Abbvie Jun.27,2031
  • Velpatasvir(PVP)

    Velpatasvir(PVP)

    Ka inoa o ka API Hōʻike Hōʻike US DMF EU DMF CEP
    Velpatasvir(PVP) HCV I-Hale    
  • Thalidomide

    ʻO Thalidomide

    Ka inoa o ka API Hōʻike Hōʻike US DMF EU DMF CEP
    ʻO Thalidomide Laʻau oncology USP/EP      
  • Ticagrelor

    Ticagrelor

    Ka inoa o ka API Hōʻike Hōʻike US DMF EU DMF CEP
    Ticagrelor ʻAiʻaʻa I-Hale 28984  
1234Aʻe >>> ʻAoʻao 1 / 4